Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | Obesity | |
| Phase 2 | GLP-1 receptorPeptide | Obesity | |
| Phase 1 | FGF21/GLP-1 receptor (dual)Peptide | MASH / NASH |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (1)
May 2027 (1)
Est. primary completion 2027-05-29 · NCT07230119 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
24 April 2026Topline resultzovaglutideZovaglutide (ZT002) Phase 2 in obesity: up to 13.8% weight loss at Week 24 (160 mg every 4 weeks)
Beijing QL Biopharmaceutical Co., Ltd. · Source ↗
Financial reports
No financial reports recorded.